title: Immunotherapy for ovarian cancer: what's next?
abstract: In the past decade, we have witnessed important gains in the treatment of ovarian cancer; however, additional advances are required to reduce mortality. With compelling evidence that ovarian cancers are immunogenic tumors, immunotherapy should be further pursued and optimized. The dramatic advances in laboratory and clinical procedures in cellular immunotherapy, along with the development of powerful immunomodulatory antibodies, create new opportunities in ovarian cancer therapeutics. Herein, we review current progress and future prospects in vaccine and adoptive T-cell therapy development as well as immunomodulatory therapy tools available for immediate clinical testing.
authors.affiliation: Ovarian Cancer Research Center, University of Pennsylvania, Philadelphia, PA, USA.
authors.forename: Lana E
authors.initials: LE
authors.lastname: Kandalaft
authors.forename: Daniel J
authors.initials: DJ
authors.lastname: Powell
authors.forename: Nathan
authors.initials: N
authors.lastname: Singh
authors.forename: George
authors.initials: G
authors.lastname: Coukos
mesh_terms: D000368:Aged; D019496:Cancer Vaccines / Q000008:administration & dosage*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D007167:Immunotherapy / Q000379:methods*; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000276:immunology* / Q000401:mortality / Q000628:therapy*; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D019496:Cancer Vaccines; D007155:Immunologic Factors